XtalPi, a leading AI drug discovery company, announces a research collaboration with Acerand Therapeutics, a biotechnology company specialized in developing best-in-class and or first-in-class drugs. The partnership will leverage XtalPi's highly accurate physics-based models and machine learning models to develop potential novel chemical entities for a cancer target.
XtalPi and Sedec have recently reached an agreement to develop novel small-molecule therapeutics targeting STAT3 palmitoylation pathway for auto immune disorder diseases treatment.
CAMBRIDGE, Mass., March 23, 2021 -- XtalPi, an artificial intelligence (AI) drug discovery and development company, is pleased to announce its investment in the Series B financing of PhoreMost, a UK-based biopharmaceutical company dedicated to Drugging the Undruggable disease targets. The investment round totaled $46 million and was led by BGF, with participation from XtalPi and a panel of new and existing investors. XtalPi Chief Strategy Officer (CSO) Dr. Alan Jiang will join PhoreMost Board of Directors.
XtalPi and Singleron will simultaneously conduct target validation and drug discovery, pursuing multiple promising targets and research paths in parallel.
Led by SoftBank Vision Fund, PICC Capital, and Morningside
XtalPi and PhoreMost sign drug discovery collaboration to discover novel inhibitors of "undruggable" targets
Combining AI Algorithms with Targeted Experiments to Solve Bottleneck Challenges in Drug Development
XtalPi team shares the timeline and preliminary results on their research of the new coronavirus.
XtalPi named as one of World's Top 20 AI Drug Development Companies
to support XtalPi’s continuous market growth and expand the application of its technology into new areas of pharmaceutical research.
Case study on how XtalPi is helping pfizer scientists predict and optimize the crystalline forms of drug candidates.
to Develop Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery